NOACs

A large-scale individual patient data meta-analysis reveals that while systemic embolic events are less common than strokes in atrial fibrillation, they carry an equivalent mortality risk. NOACs significantly reduce this risk by 29% compared to warfarin, especially in high-risk phenotypes.